drugset / Trial / NCT00585507
Efficacy and Safety of 500mg of Fulvestrant
Phase 2
Active not recruiting
40 enrolled
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital · collabDana-Farber Cancer Institute · collabLowell General Hospital · collabMassachusetts General Hospital · collabSouth Shore Hospital · collabUniversity of Colorado, Denver · collabUniversity of Maryland Greenebaum Cancer Center · collab
NaSingle-groupOpen-labelTreatment
Summary
Fulvestrant has proven effective in the treatment of hormone receptor positive metastatic breast cancer. The dose used in studies so far has been well tolerated and may be too low for optimal effectiveness. In this study, a higher dose will be used to see whether an improved outcome will result.
Timeline
- Start
- 2004-04
- Primary completion
- 2027-03-15
- Completion
- 2027-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fulvestrant | Small molecule | 500 mg | Intramuscular |